Role of 18F-FDG PET/CT in Large Vessel Vasculitis and Polymyalgia Rheumatica

J Nucl Med. 2023 Apr;64(4):515-521. doi: 10.2967/jnumed.122.265016.

Abstract

Systemic vasculitides comprise a group of autoimmune diseases affecting blood vessels, including large vessel vasculitis (LVV) and medium-sized vessel vasculitis such as giant cell arteritis (GCA) and Takayasu arteritis (TAK). GCA frequently overlaps with polymyalgia rheumatica (PMR), a rheumatic inflammatory condition affecting bursae, tendons or tendon sheaths, and joints. 18F-FDG PET/CT plays an important role in the diagnostic work-up of GCA, PMR, and TAK and is increasingly used to monitor treatment response. This continuing education article provides up-to-date guidance on the role of 18F-FDG PET/CT in patients with LVV, medium-sized vessel vasculitis, and PMR. It provides a general introduction on the clinical presentation and challenges in the diagnostic work-up of LVV and medium-sized vessel vasculitis, with a focus on the 2 major LVV subtypes: GCA, including PMR, and TAK. Next, practice points to perform and interpret the results of 18F-FDG PET/CT are described in line with the published procedure recommendations. Furthermore, the diagnostic performance and its role for treatment monitoring are discussed, taking into account recent international recommendations for the use of imaging in LVV and medium-sized vessel vasculitis in clinical practice. This is illustrated by several clinically representative PET/CT scan examples. Lastly, knowledge of limitations and pitfalls is essential to understand the role of 18F-FDG PET/CT in LVV, medium-sized vessel vasculitis, and PMR. Challenges and opportunities, as well as future research and conclusions, are highlighted. Learning objectives provide up-to-date guidance for the role of 18F-FDG PET/CT in patients with suspected LVV, medium-sized vessel vasculitis, and PMR.

Keywords: 18F-FDG PET/CT; PMR; cranial GCA; large vessel vasculitis; procedures.

MeSH terms

  • Fluorodeoxyglucose F18 / therapeutic use
  • Giant Cell Arteritis* / diagnostic imaging
  • Giant Cell Arteritis* / drug therapy
  • Humans
  • Polymyalgia Rheumatica* / diagnostic imaging
  • Polymyalgia Rheumatica* / drug therapy
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography

Substances

  • Fluorodeoxyglucose F18